Cat No. 12-B11

Saracatinib (AZD0530)

10 mg

For research purposes only

Saracatinib is a highly selective, orally available Src/Abl kinase inhibitor. It is highly selective for Src and Abl kinases against a large range of tyrosine and serine-threonine kinases (VEGFR, FGFR, c-Kit etc,) Saracatinib exerts its activity through ATP competitive and reversible inhibition of the target enzyme. Saracatinib has been shown to inhibit tumor growth in a manner independent of dose and inhibits phosphorylation of focal adhesion kinase (FAK) and paxillin in a dose-dependent manner in a Calu-6 Xenograft model.

TECHNICAL INFORMATION



Other Names: AZD0530

Chemical Formula: $C_{27}H_{32}ClN_5O_5$

CAS Number: 379231-04-6

Molecular Weight: 542.03

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 200 mg/ml. If precipitate is observed, vortex for 5 minutes.

REFERENCES

1. Hennequin et al. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 49(22):6465-88.
2. Green et al. (2009) Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 3 (3):248-61.
3. Rajeshkumar et al. (2009) Antitumor effects and bi-omarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res. 15(12):4138-46.